Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.30
(
-0.13%
)
Bitcoin
70,749.02
(
1.22%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: spartex post# 58624

Monday, 06/23/2008 7:42:14 AM

Monday, June 23, 2008 7:42:14 AM

Post# of 257262
ACHN will not spend any more of its own money on its HIV NRTI drug, elvucitabine, according to the CEO’s comments on the recent Needham webcast. This is probably a good decision—the drug’s commercial prospects are poor for the reasons mentioned in #msg-26540327.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now